{
  "docId": "019de514-f120-743f-9d00-70915b7d1fa5",
  "docSlug": "a9055659e75fd1b92a3c529616eb6953",
  "documentTitle": "Bausch+Lomb | Results Presentation Deck | 49 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch + Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 49,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 24,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de514-f120-743f-9d00-70915b7d1fa5/10",
  "deckHref": "/decks/019de514-f120-743f-9d00-70915b7d1fa5",
  "deckJsonHref": "/decks/019de514-f120-743f-9d00-70915b7d1fa5.json",
  "deckAnchorHref": "/decks/019de514-f120-743f-9d00-70915b7d1fa5#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.33,
        "w": 0.27,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Total Company Revenue\nMillions USD\n1,001\n54 FX Impact4\n947\n4Q21\n996\n4Q22",
      "attrs": {},
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2827870c-c173-44d6-97f8-170e2d2962ae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.41,
        "w": 0.19,
        "x": 0.77,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Ophthalmic Pharmaceuticals\n61%\n$182M\n39%\nU.S.\nInternational",
      "attrs": {},
      "subkind": "donut",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "54309a8e-8c51-420a-928b-8fb5b37916cc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.41,
        "w": 0.2,
        "x": 0.34,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Vision Care\n35%\n$626M\n65%\nConsumer\nContact Lens",
      "attrs": {},
      "subkind": "donut",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bd12475b-1e05-4b68-ad9d-1f3dba5a11a7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.41,
        "w": 0.19,
        "x": 0.56,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Surgical\n27%\n53%\n$188M\n20%\nImplantables\nEquipment\nConsumables/Other",
      "attrs": {},
      "subkind": "donut",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd7272ff-9892-45bd-bf86-70b5acd8e773",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.23,
        "w": 0.24,
        "x": 0.07,
        "y": 0.63
      },
      "kind": "list",
      "text": "Seventh consecutive quarter of organic revenue growth1,2\nSecond consecutive quarter of organic revenue growth across all three segments1,2\nChina saw shift towards positive signs of economic recovery following policy adjustments in the middle of the 4Q22",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "103207de-9efa-4c72-a612-082a10947507",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.19,
        "x": 0.77,
        "y": 0.66
      },
      "kind": "list",
      "text": "Vyzulta® saw ~18% TRx growth³ in 4Q22; continued geo-expansion\nPositive early stages of XIPERE® launch\nCOVID recovery in China impacted International portfolio\nCapitalized on competitor supply challenges to drive U.S. Gx growth",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "273d2f1e-32cd-40c7-9545-b09e057c407f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.19,
        "x": 0.35,
        "y": 0.66
      },
      "kind": "list",
      "text": "Strong demand for key franchises:\nLumify® (+25% reported revenue growth)\nOcuvite® + PreserVision® (+13% reported revenue growth)\nDaily SiHy (+85% reported revenue growth)\nBausch + Lomb ULTRA® (+2% reported revenue growth)",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c82a1efe-d05f-404c-abd7-d40a481d70f7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.19,
        "x": 0.56,
        "y": 0.66
      },
      "kind": "list",
      "text": "Growth in implantables (+2% reported revenue growth; +13% organic revenue growth1.2), driven by premium and standard IOLS\nStrong demand for consumables (5% reported revenue decline; 3% organic revenue growth1.2), driven by an increase in cataract and retina procedures\nEquipment impacted by supply availability",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ccf85929-6133-48ab-b310-8570f5c8d057",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.05,
        "x": 0.41,
        "y": 0.62
      },
      "kind": "metric",
      "text": "+5%",
      "attrs": {},
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6bb88ba7-c95e-4734-83bd-2b1e24ddf1b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.23,
        "x": 0.08,
        "y": 0.55
      },
      "kind": "metric",
      "text": "+5% organic revenue1,2 growth",
      "attrs": {},
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91a5a2b8-d5cf-457c-8b4f-7ec855455c62",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.05,
        "x": 0.84,
        "y": 0.62
      },
      "kind": "metric",
      "text": "+7%",
      "attrs": {},
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92ed566d-2bbe-41de-b365-69df1fa1cf57",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.05,
        "x": 0.64,
        "y": 0.62
      },
      "kind": "metric",
      "text": "+4%",
      "attrs": {},
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6bdb2b5-4c44-41d8-86b1-f8d5a0d7f112",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.65,
        "x": 0.16,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "1. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.\n2. Organic revenue growth/change, a non-GAAP ratio, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.\n3. IQVIA NPA monthly. U.S. only.\n4. FX impact is determined by comparing 2022 reported amounts adjusted to exclude currency impact, calculated using 2021 monthly average exchange rates, to the actual 2021 reported amounts.",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ba817e3-2635-4870-86cd-db8abc01ebf5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.69,
        "x": 0.045,
        "y": 0.075
      },
      "kind": "title",
      "text": "4Q22 Financial Highlights & Segment Drivers",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68d3a28a-795d-46b2-bc59-055572be55a7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 10,
      "beatId": "7dc62337-b2ed-4c41-8d32-808d2f972bf7",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The presentation showcases the company's strong financial performance and strategic advancements, providing satisfaction to investors",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 10,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "d15671c2-99b6-48fa-89dc-6302733eef20",
      "evidence": "The presentation highlights the company's financial performance and strategic advancements, implying the consequences of not investing in Bausch + Lomb",
      "position": 0,
      "objective": "Emphasize the importance of Bausch + Lomb's solutions by highlighting the cost of inaction",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}